Schizophrenia Clinical Trial
Official title:
Clozapine Vs. Risperidone for People With First Episode Schizophrenia and Co-Occurring Substance Use Disorder
Many individuals with schizophrenia abuse cannabis at the onset of their illness, portending a poorer course of illness and poorer treatment response. Preliminary evidence suggests that clozapine may uniquely reduce substance use in patients with schizophrenia. The purpose of this study is to establish an effective methodology for studying early treatment with clozapine in patients with co-occurring schizophrenia and cannabis use disorder, while generating pilot data comparing clozapine vs. risperidone on substance use, psychiatric symptoms, side effects, and treatment discontinuation.
Schizophrenia is a relapsing disorder that produces profound effects on those afflicted once
it becomes chronic, often leading to a severe and long-term disability. However, during the
initial years of illness many patients are more treatment responsive and may achieve
substantial periods of remission. Comorbid substance use disorder, a common concomitant of
schizophrenia, is associated with increases in morbidity and mortality. Within the early
phases of schizophrenia, comorbid cannabis use disorder (CUD), the most common comorbid
disorder (approximately 50%), appears to be linked to a poor outcome in these patients, and
may be a factor in their long-term deterioration. While data indicate that first episode
patients presenting with comorbid CUD have an earlier onset of illness and a poorer outcome
than those without CUD, continued cannabis use after antipsychotic treatment, which occurs in
approximately 50% of these patients in the initial months after hospitalization, is
associated with an even worse outcome. The apparent "toxicity" of cannabis use in first
episode patients is paralleled by data from chronic patients, in whom CUD is associated with
clinical exacerbations, non-compliance with treatment, poor global functioning, and increased
relapse. A growing body of data suggests that a critical period exists in patients with
schizophrenia during the early phases of psychosis in which symptoms and functioning continue
to worsen, and that treatment with antipsychotic medications during this period may improve
the natural course of the disorder. While the availability of novel antipsychotic medications
has sparked further research in the early phases of schizophrenia, there have been few
studies including clozapine (CLOZ). We hypothesize that CLOZ may be more effective than other
novel agents in controlling cannabis use in patients with first episode schizophrenia who are
comorbid for CUD. We postulate that standard antipsychotic medications do not decrease
substance use in this population largely because they do not restore normal functioning of
the dysfunctional dopamine (DA) pathways. CLOZ, by contrast, through its varied actions on
dopaminergic, serotonergic and, particularly, noradrenergic neurons, coupled with its weak D2
and potent noradrenergic alpha2 blocking ability, may tend to have a "normalizing" effect on
the signal detection capability of these dysfunctional DA systems. CLOZ is rarely used in
first episode patients even though it is generally considered a highly effective medication,
and more likely to prevent relapses than typical antipsychotics in both treatment refractory
and non-refractory populations. While side effects of CLOZ are a clinical concern and need to
be taken seriously, experience over the past 2 decades has increased the comfort level for
its use. For example, agranulocytosis has actually occurred in 0.37% with implementation of
the required white count monitoring system, and granulocyte stimulating therapy has provided
an effective treatment for those few patients who do develop agranulocytosis. Gradual dose
titration schedules appear to reduce risk for seizure and myocarditis, and experience in
first episode patients suggesting that the clinically effective dose of CLOZ is lower than in
chronic patients indicates that these risk should be even lower. If our hypothesis is
correct, CLOZ, despite its side effect profile, may have a key therapeutic role in these
patients, a role with important public health implications. Yet without a clear demonstration
of the benefit/risk and benefit/burden profiles of its use, the naturalistic experiment of
assessing the overall effectiveness of CLOZ in first episode patients who are comorbid for
CUD is unlikely to be undertaken.
This study is enrolling individuals who are in their first episode of schizophrenia or
schizoaffective disorder and who are currently using cannabis. Study participants undergo a
screening visit including the Structured Clinical Interview for Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV) for diagnostic evaluation, and a physical examination,
blood tests, and review of medical, psychiatric, and substance use history. Following the
screening visit, eligible participants are randomly assigned to single-blind treatment with
clozapine or risperidone for 24 weeks. Participants assigned to clozapine initially receive a
daily dose of 12.5 mg, which is carefully titrated to the lowest dose necessary to manage
psychotic symptoms and well tolerated. Participants assigned to risperidone initially receive
0.5 mg daily and are carefully titrated in the same fashion. Cross titration off of the
previous antipsychotic (if any) and onto study medication is completed within 2-4 weeks.
Participants on clozapine have weekly blood tests. Concomitant medications are minimized and
kept stable throughout the protocol except as needed to manage side effects or urgent
clinical symptoms. Study medication, psychiatric visits, assessments and labwork are all
provided without charge to participants. Study visits take place once a week. At study
visits, medication side effects, physical and psychiatric symptoms, substance use, and
treatment services received are assessed. A Lifestyle Intervention is also provided to help
prevent metabolic side-effects in this vulnerable population, and assist with recovery. The
investigators meet weekly to review clinical care and manage any variations in study
protocol.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |